ESMO 2024 - Sven Schaffer
The European Society for Medical Oncology (ESMO) 2024 meeting was a well-attended affair at the sprawling Fira Gran Via centre in Barcelona.
Newsletters and Deep Dive digital magazine
The European Society for Medical Oncology (ESMO) 2024 meeting was a well-attended affair at the sprawling Fira Gran Via centre in Barcelona.
Pfizer's anti-GDF-15 antibody ponsegromab was able to achieve weight gain in cancer patients with cachexia – a life-threatening metabolic syndrome caused by the underlying disease with no a
Johnson & Johnson is planning a phase 3 programme for Rybrevant in colorectal cancer as a follow-up to its first indication in non-small cell lung cancer (NSCLC), after reporting encour
AstraZeneca has revealed the data for Imfinzi in muscle-invasive bladder cancer (MIBC) that it hopes will be enough to secure FDA approval – although the jury is out on that.
Rates of cancer among people aged 24 and below are rising fast, but health systems are often not catering well enough to the specific needs of this age group.
Editor's Picks
Newsletters and Deep Dive
digital magazine